Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (BRIDGE)

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Schetelig Johannes, Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT01295307
First received: February 4, 2011
Last updated: October 6, 2015
Last verified: October 2015